Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change

BACKGROUND: Eluxadoline, a United States Food and Drug Administration (FDA)-approved treatment for irritable bowel syndrome with diarrhea (IBS-D), underwent a change to its US prescribing information on 21 April 2017, contraindicating it in patients without a gallbladder due to increased risk of pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cash, Brooks D., Lacy, Brian E., Watton, Cheryl, Schoenfeld, Philip S., Weissman, Darren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042552/
https://www.ncbi.nlm.nih.gov/pubmed/33953798
http://dx.doi.org/10.1177/17562848211001725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042552/
https://www.ncbi.nlm.nih.gov/pubmed/33953798
http://dx.doi.org/10.1177/17562848211001725

Ejemplares similares